modafinil has been researched along with Meningioma in 1 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Meningioma: A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function, and treatment effect." | 9.20 | Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. ( Bryant, D; Case, D; Chan, MD; Grisell, D; Lesser, GJ; Lu, L; Monitto, DC; Naughton, MJ; Page, BR; Rapp, SR; Savona, SR; Shah, S; Shaw, EG, 2015) |
| "A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function, and treatment effect." | 5.20 | Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. ( Bryant, D; Case, D; Chan, MD; Grisell, D; Lesser, GJ; Lu, L; Monitto, DC; Naughton, MJ; Page, BR; Rapp, SR; Savona, SR; Shah, S; Shaw, EG, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Page, BR | 1 |
| Shaw, EG | 1 |
| Lu, L | 1 |
| Bryant, D | 1 |
| Grisell, D | 1 |
| Lesser, GJ | 1 |
| Monitto, DC | 1 |
| Naughton, MJ | 1 |
| Rapp, SR | 1 |
| Savona, SR | 1 |
| Shah, S | 1 |
| Case, D | 1 |
| Chan, MD | 1 |
1 trial available for modafinil and Meningioma
| Article | Year |
|---|---|
Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue.
Topics: Adult; Aged; Benzhydryl Compounds; Brain Neoplasms; Double-Blind Method; Fatigue; Female; Glioblasto | 2015 |